Iovance Biotherapeutics, Inc. filings document a biotechnology company focused on polyclonal TIL therapies, including disclosures tied to Amtagvi, Proleukin, lifileucel, and broader solid-tumor cell therapy programs. Its Form 8-K reports cover operating results, financial condition, corporate presentations, clinical or regulatory disclosures, and material-event updates.
The filing record also includes proxy materials covering director elections, executive compensation, shareholder voting matters, and board governance. Capital-structure disclosures include common stock matters, registration-statement references, and material agreements related to an at-the-market offering program.
At Iovance Biotherapeutics, Inc., director and Interim CEO & General Counsel Frederick G. Vogt exercised a fully vested stock option on November 11, 2026, covering 200,000 common shares at an exercise price of $7.55 per share. The option was scheduled to expire November 14, 2026. The issuer withheld 186,651 shares for the exercise price and 4,652 for mandatory tax withholding; no shares were sold in the open market. The exercise increased Vogt's holdings by 8,697 shares and produced no cash proceeds.
Iovance Biotherapeutics, Inc. (IOVA) Chief Commercial Officer Daniel Gordon Kirby had 10,000 restricted stock units vest on November 10, 2026, converting into 10,000 common shares. The issuer withheld 3,935 common shares to meet mandatory tax withholding; this was not an open-market sale. The report lists 50,003 remaining RSUs from a February 10, 2025 grant, which will vest in equal quarterly installments; that count excludes any other RSUs he holds.
Iovance Biotherapeutics, Inc. Chief Financial Officer Corleen M. Roche had 12,500 restricted stock units vest on November 6, 2026, and acquired 12,500 common shares; each unit represents a contingent right to one common share. The issuer withheld 5,311 common shares for mandatory tax withholding upon vesting, not as an open-market sale. Afterward, 87,505 RSUs remained from the August 6, 2025 grant, excluding her other RSUs; the remainder will vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. common stock was the subject of State Street Corporation’s beneficial-ownership report: 21,695,003 shares, or 4.8%, as of September 30, 2026. State Street reported shared voting power over 20,523,410 shares and shared dispositive power over 21,695,003 shares; sole voting and dispositive power were each reported as 0.
Iovance Biotherapeutics, Inc. updated its corporate presentation, which reports full-year 2026 revenue guidance raised to $410 million–$420 million from $350 million–$370 million; the midpoint is $55 million, or ~15%, above the prior range. Third-quarter 2026 revenue was ~$122 million, with ~80% year-over-year and ~22% quarter-over-quarter growth. Cash position was ~$382 million as of September 30, 2026, comprising cash, cash equivalents, short-term investments and restricted cash; the presentation describes a cash runway well into 2029. Margin from cost of sales was ~60% in Q3 and 54% year to date, excluding depreciation and amortization.
Lifileucel is in the ongoing Phase 3 TILVANCE-301 trial for frontline advanced melanoma, comparing lifileucel plus pembrolizumab with pembrolizumab alone. Interim data as of October 14, 2026, including partial independent review committee data, reported a 24.6% objective response rate (17/69) in the non-squamous NSCLC KRAS prior-treatment sensitivity population and 59.1% (13/22) in a KRAS-wild-type, HER2-wild-type, ever-smoker subgroup. Planned supplemental BLA submissions are listed for NSCLC cohorts in 2027 and 2028, and soft-tissue sarcoma cohorts in 2028–2029.
Iovance Biotherapeutics, Inc. (IOVA) reported third-quarter 2026 net product revenue of $121.469 million, compared with $67.455 million in third-quarter 2025. Amtagvi generated $101.602 million and Proleukin $19.867 million. Quarterly net loss was $22.271 million, versus $91.253 million a year earlier.
For the nine months ended September 30, 2026, revenue was $292.212 million versus $176.731 million, net loss was $148.631 million versus $319.074 million, and net cash used in operating activities was $137.385 million versus $249.843 million. At September 30, cash, cash equivalents, short-term investments and restricted cash totaled $382.3 million. Management said available capital was sufficient to fund planned operating expenses and capital expenditures for at least the next twelve months from the date the financial statements are issued.
Amtagvi received marketing authorization with conditions in Australia on June 4, 2026. Iovance resubmitted its UK marketing authorization application with additional information in July 2026; potential approval is expected in the first quarter of 2027. The company plans to resubmit an EU application in 2027.
Iovance Biotherapeutics reported third-quarter 2026 total revenue of $121.469 million, compared with $67.455 million in the third quarter of 2025; the company described year-over-year growth as approximately 80%. U.S. Amtagvi revenue increased approximately 77%, and gross margin increased to approximately 60%. Net loss was $22.271 million, versus $91.253 million a year earlier. Iovance said it remains on track for full-year 2026 total revenue of $410 million to $420 million.
In clinical updates, Iovance reported a 24.6% objective response rate among 69 patients with non-squamous metastatic non-small-cell lung cancer and a 59.1% rate in a biomarker-selected subgroup; the POSITILITY trial is underway. The company reported a confirmed 55.6% response rate among 9 patients with UPS and DDLPS, with the SARATOGA registrational trial underway. Iovance is completing enrollment in Cohorts 1 and 2 of IOV-LUN-202 and preparing for a supplemental Biologics License Application submission. More than 1,000 patients have been commercially treated with Amtagvi.
Iovance Biotherapeutics, Inc. reported updated Phase 2 IOV-LUN-202 results: 17 of 69 patients with previously treated non-squamous metastatic non-small-cell lung cancer responded, an objective response rate of 24.6% as of October 14, 2026. A retrospective subgroup defined by KRAS wild-type, HER2 wild-type and current or former smoking had 13 responses among 22 patients, an objective response rate of 59.1%. Fifteen responses were confirmed and two were unconfirmed partial responses awaiting confirmation; independent radiologic assessments are ongoing.
POSITILITY will prospectively evaluate the biomarker-enriched approach, with enrollment planned to begin in November 2026 and a potential registrational pathway subject to FDA feedback. Cohorts 1 and 2 are completing enrollment, and an sBLA for lifileucel in non-squamous mNSCLC is planned for 2027. Lifileucel remains investigational for mNSCLC.
Iovance Biotherapeutics updated its corporate presentation for healthcare conferences, analysts and stockholders, covering its commercial business, financial outlook and TIL pipeline. It reported approximately $99 million in second-quarter 2026 revenue, more than 10% above guidance, and approximately 66% year-over-year growth. Full-year 2026 revenue guidance is $410 million to $420 million, with a midpoint $55 million, or approximately 15%, above the prior $350 million to $370 million range.
Its cash position, defined as cash, cash equivalents, short-term investments and restricted cash, was approximately $304 million as of June 30, 2026, with runway into the second half of 2028. Iovance reported a 56% margin from cost of sales in 2Q26, excluding depreciation and amortization, and 50% year to date. It lists approximately 100 authorized treatment centers as of October 5, 2026, and annual manufacturing capacity above 5,000 patients across North America, Europe and APAC.
In nonsquamous metastatic non-small cell lung cancer, interim data showed a 25.6% objective response rate among 39 patients; median duration of response was not reached at a median follow-up of 25.4 months. The presentation also outlines a Phase 3 frontline melanoma trial and Phase 2 registrational studies in lung cancer and soft-tissue sarcoma.
Iovance Biotherapeutics, Inc. (IOVA) reported direct equity awards to Chief Medical Officer Noah Berkowitz on September 30, 2026: options covering 135,000 shares, 180,000 restricted stock units, and 135,000 performance stock units. The options have a $14.82 exercise price and expire September 30, 2036. Provided he remains employed with Iovance on the applicable dates, one-third of the options and RSUs vest on the grant’s one-year anniversary; the remainder vest in eight equal quarterly installments over the next two years, beginning with the first quarter after that anniversary. Each RSU represents a contingent right to one common share. Up to 135,000 shares underlying the PSUs may be earned subject to regulatory milestones; earned PSUs vest when Iovance publicly discloses receipt of certain milestones on Form 8-K. Each PSU converts into one common share.